Zobrazeno 1 - 10
of 10
pro vyhledávání: '"T. Ceron-Lizarraga"'
Autor:
Oscar Arrieta, Norma Hernández-Pedro, Julio Sotelo, Daniel Rembao, B Segura-Pacheco, C. H. González-de la Rosa, Daniela Morales-Espinosa, T. Ceron-Lizarraga, B Pineda-Olvera, P. Guevara-Salazar
Publikováno v:
British Journal of Cancer
Astrocytomas develop intense vascular proliferation, essential for tumour growth and invasiveness. Angiotensin II (ANGII) was initially described as a vasoconstrictor; recent studies have shown its participation in cellular proliferation, vascularisa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b777d220de4f254aa3b347ad993a7299
https://doi.org/10.1038/sj.bjc.6604431
https://doi.org/10.1038/sj.bjc.6604431
Autor:
Julio Sotelo, Vinicio Granados-Soto, Benjamín Pineda, T. Ceron-Lizarraga, Norma Hernández-Pedro, Luis Manuel Martínez-Barrera, M.C. Fernández-González Aragón, Graciela Ordoñez, Miguel Angel Rios-Trejo, Alma D. Campos-Parra, David Saavedra-Perez, Alma Ortiz-Plata, Oscar Arrieta
Objective: To evaluate the effect of all- trans retinoic acid (ATRA) as treatment for chemotherapy-induced peripheral neuropathy in an experimental animal model and in a randomized, double-blinded, controlled trial in patients with non-small-cell lun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d311e6055aca6b84f3c8e0e1c144ffc
https://europepmc.org/articles/PMC3171957/
https://europepmc.org/articles/PMC3171957/
Autor:
Carlos Enrique Rojas-Marín, T. Ceron-Lizarraga, Oscar Arrieta, Elena Aréchaga-Ocampo, Norma Hernández-Pedro, Claudia H. Gonzalez-De la Rosa, Luis Manuel Martínez-Barrera, María E. Vázquez-Manríquez, Miguel Á. Álvarez-Avitia, Miguel Angel Rios-Trejo, Jaime de la Garza, Geraldine Villanueva-Rodríguez
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(21)
Purpose This randomized phase II trial evaluated whether the combination of cisplatin and paclitaxel (PC) plus all-trans retinoic acid (ATRA) increases response rate (RR) and progression-free survival (PFS) in patients with advanced non–small-cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6bb6f5f4c513146932039703c0147cf
https://pubmed.ncbi.nlm.nih.gov/20547984
https://pubmed.ncbi.nlm.nih.gov/20547984
Autor:
T. Ceron-Lizarraga, Jorge García-Leiva, Daniela Morales-Espinosa, Oscar Arrieta, Judith Meza-Junco, Armando Gamboa-Domínguez
Publikováno v:
Annals of Hepatology, Vol 5, Iss 4, Pp 263-267 (2006)
Hepatocellular carcinoma is the fifth most common malignant neoplasm worldwide. Most patients are not candidates to surgical treatment. The prognosis of this neoplasm is poor, with an overall survival rate of 8 weeks in unresectable tumors. Estrogen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b31ecdae3a74c4d1e58e19a42031a521
https://pubmed.ncbi.nlm.nih.gov/17151578
https://pubmed.ncbi.nlm.nih.gov/17151578
Autor:
E. Arechaga, Miguel Angel Rios-Trejo, T. Ceron-Lizarraga, G. Villanueva, Oscar Arrieta, M. Alvarez-Avitia, D. Pachuca, Luis Martinez, H. González-De la Rosa, J. de la Garza
Publikováno v:
European Journal of Cancer Supplements. 7:23
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79d55c08bb8007c267e395d85a2c48e6
https://doi.org/10.1016/s1359-6349(09)72090-7
https://doi.org/10.1016/s1359-6349(09)72090-7
Autor:
J. Reyes-Contreras, Eduardo Tellez, P. Castillo, J. G. De La Garza-Salazar, Daniela Morales-Espinosa, T. Ceron-Lizarraga, Luis Manuel Martínez-Barrera, O. G. Arrieta Rodriguez, Diana Flores-Estrada, N. Hernandez Pedro
Publikováno v:
Journal of Clinical Oncology. 25:18029-18029
18029 Background: Erlotinib, a tyrosine kinase inhibitor, has improved survival and quality of life in patients with non-small cell lung cancer (NSCLC) after fist-line or second-line chemotherapy. Asian origin, adenocarcinoma histology, female gender
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5c9ef568f3beff3e440521180c3b209
https://doi.org/10.1200/jco.2007.25.18_suppl.18029
https://doi.org/10.1200/jco.2007.25.18_suppl.18029
Publikováno v:
Journal of Clinical Oncology. 24:10632-10632
10632 Background: Angiotensin II (ANG II) is the main effector peptide of the Renin-Angiotensin-Aldosterone System. ANG II has multiple physiologic effects and recent studies have demonstrated that is an angiogenic factor in non-tumoral experimental
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95f6e1314bb01d74b8480cddebaead9f
https://doi.org/10.1200/jco.2006.24.18_suppl.10632
https://doi.org/10.1200/jco.2006.24.18_suppl.10632
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.